Merck's Victrelis still lags Incivek despite improvement in Europe
This article was originally published in Scrip
Executive Summary
Merck & Co's Victrelis has upped its market share in the battle of the protease inhibitors, but it still lags a long way behind Vertex Pharmaceuticals/Janssen's Incivek/Incivo. Victrelis (boceprevir) has grown its share to over 40% in the US (compared with around 25% in autumn last year) and even exceeded 50% in some markets, including France, Germany, Canada, Norway and Denmark, according to Merck's head of global human health, Adam Schechter.